Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.70 |
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275920 | 0.89 | ALDH1A1 (0.70) | RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4741253 | 0.89 | MEN1 (0.76) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL11048619 | 0.89 | MEN1 (0.76) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4548043 | 0.83 | SMN1; SMN2 (0.74) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL13556605 | 0.83 | RAB9A (0.65) | RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4548128 | 0.83 | RAB9A (0.69) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL13556601 | 0.83 | MAPT (0.61) | RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL493839 | 0.82 | RAB9A (0.81) | RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL10192061 | 0.82 | RAB9A (0.81) | RAB9ANPC1ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL22103910 | 0.82 | CNR1 (0.83) | RAB9ANPC1ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| EP-0382411-B1 | Delivery of cytotoxic agents | LILLY CO ELI (US) | 1994-12-07 | — | — | EP | claimed |
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| CN-113271941-B | Urea derivatives for the treatment and/or prophylaxis of cancer | 法国国家科学研究中心 | 2024-09-20 | — | — | CN | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2020079184-A2 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-04-23 | — | — | WO | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-4444863-A | UREA COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885NPC1 1296/4885ALDH1A1 2667/4885 |
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | RAB9A 1810/4885NPC1 1422/4885ALDH1A1 4846/4885 |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885NPC1 927/4885ALDH1A1 994/4885 |
| US-20210380547-A1 | UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER | CXCR1, CXCR2, CXCR6 | RAB9A 1386/4885NPC1 331/4885ALDH1A1 639/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | RAB9A 2178/4885NPC1 1090/4885ALDH1A1 1272/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | RAB9A 2178/4885NPC1 1090/4885ALDH1A1 1272/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885NPC1 1296/4885ALDH1A1 2667/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885NPC1 1296/4885ALDH1A1 2667/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | RAB9A 3091/4885NPC1 1296/4885ALDH1A1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.